[Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].

Jiang, R; Dai, L M J; Sha, Y Q; Xia, Y; Miao, Y; Qin, S C; Wu, W; Qiu, J Y; Bi, H L; Wang, L; Fan, L; Xu, W; Li, J Y; Zhu, H Y

Jiang, R; Dai, L M J; Sha, Y Q; Xia, Y; Miao, Y; Qin, S C; Wu, W; Qiu, J Y; Bi, H L; Wang, L; Fan, L; Xu, W; Li, J Y; Zhu, H Y.

Affiliation

Jiang R; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Dai LMJ; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Sha YQ; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Xia Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Miao Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Qin SC; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Wu W; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Qiu JY; Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Bi HL; Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Wang L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Fan L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Xu W; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Li JY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
Zhu HY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.

Zhonghua Xue Ye Xue Za Zhi ; 44(3): 247-250, 2023 Mar 14.

Article in Zh | MEDLINE | ID: mdl-37356988

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Agents Limits: Humans Language: Zh Journal: Zhonghua Xue Ye Xue Za Zhi Year: 2023 Document type: Article Affiliation country: Publication country: CHINA / CN / REPUBLIC OF CHINA

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google